Splice isoforms as therapeutic targets for colorectal cancer

Carcinogenesis

Volumn 33, Issue 12, 2012, Pages 2311-2319

  Miura, Koh ^a   Fujibuchi, Wataru ^b   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; BACULOVIRAL INHIBITOR OF APOPTOSIS PROTEIN REPEAT CONTAINING 5; BEVACIZUMAB; CYCLIN D1; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ISOPROTEIN; K RAS PROTEIN; MESSENGER RNA; PREGNANE X RECEPTOR; RIBONUCLEASE H; RIBOZYME; SLC39A14 PROTEIN; SMALL INTERFERING RNA; SURVIVIN; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; COLORECTAL CANCER; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION;

ALTERNATIVE SPLICING; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYCLIN D1; DIHYDROURACIL DEHYDROGENASE (NADP); GLUCURONOSYLTRANSFERASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PROTEIN ISOFORMS; RECEPTORS, STEROID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84870341344     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs347     Document Type: Review

References (94)

1. Jemal, A. et al. (2011) Global cancer statistics. CA. Cancer J. Clin., 61, 69-90.
2. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
3. Miura, K. et al. (2011) Alternative pre-mRNA splicing in digestive tract malignancy. Cancer Sci., 102, 309-316.
4. Wang, E.T. et al. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature, 456, 470-476.
5. Yoshida, K. et al. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.
6. Moore, M.J. et al. (2010) An alternative splicing network links cell-cycle control to apoptosis. Cell, 142, 625-636.
7. Chow, L.T. et al. (1977) An amazing sequence arrangement at the 5' ends of adenovirus 2 messenger RNA. Cell, 12, 1-8.
8. Klessig, D.F. (1977) Two adenovirus mRNAs have a common 5' terminal leader sequence encoded at least 10 kb upstream from their main coding regions. Cell, 12, 9-21.
9. Chen, M. et al. (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol., 10, 741-754.
10. Warzecha, C.C. et al. (2009) ESRP1 and ESRP2 are epithelial cell-typespecific regulators of FGFR2 splicing. Mol. Cell, 33, 591-601.
11. Luco, R.F. et al. (2011) Epigenetics in alternative pre-mRNA splicing. Cell, 144, 16-26.
12. Amankwah, E.K. et al. (2012) Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis, 33, 1259-1269.
13. Rennel, E.S. et al. (2009) Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol., 5, 703-712.
14. Bates, D.O. et al. (2002) VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res., 62, 4123-4131.
15. Harper, S.J. et al. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer, 8, 880-887.
16. Rennel, E.S. et al. (2009) VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo. Br. J. Cancer, 101, 1183-1193.
17. Presta, L.G. et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 57, 4593-4599.
18. Muller, Y.A. et al. (1997) Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc. Natl. Acad. Sci. U.S.A., 94, 7192-7197.
19. Troiani, T. et al. (2012) Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opin. Investig. Drugs, 21, 949-959.
20. Gragoudas, E.S. et al.; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. (2004) Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med., 351, 2805-2816.
21. Nowak, D.G. et al. (2008) Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J. Cell. Sci., 121(Pt 20), 3487-3495.
22. Haaz, M.C. et al. (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 58, 468-472.
23. Rivory, L.P. et al. (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin. Cancer Res., 3, 1261-1266.
24. Ando, Y. et al. (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 60, 6921-6926.
25. Sai, K. et al. (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther., 75, 501-515.
26. Innocenti, F. et al. (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol., 22, 1382-1388.
27. Gong, Q.H. et al. (2001) Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics, 11, 357-368.
28. Ritter, J.K. et al. (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem., 267, 3257-3261.
29. Girard, H. et al. (2007) Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet. Genomics, 17, 1077-1089.
30. Bellemare, J. et al. (2011) Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans. J. Pathol., 223, 425-435.
31. Bellemare, J. et al. (2010) Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro. Drug Metab. Dispos., 38, 1785-1789.
32. Raynal, C. et al. (2010) Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer, 9, 46.
33. Gardner-Stephen, D. et al. (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab. Dispos., 32, 340-347.
34. Solier, S. et al. (2010) Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res., 70, 8055-8065.
35. Lew, D.J. et al. (1991) Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell, 66, 1197-1206.
36. Arber, N. et al. (1996) Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology, 110, 669-674.
37. Wang, Q.S. et al. (1998) Altered expression of cyclin D1 and cyclindependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Carcinogenesis, 19, 2001-2006.
38. Jiang, W. et al. (1993) Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. U.S.A., 90, 9026-9030.
39. Zwijsen, R.M. et al. (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell, 88, 405-415.
40. Li, Z. et al. (2010) Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res., 70, 8802-8811.
41. Witzel, I.I. et al. (2010) Regulation of cyclin D1 gene expression. Biochem. Soc. Trans., 38, 217-222.
42. Knudsen, K.E. (2006) The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div., 1, 15.
43. Betticher, D.C. et al. (1995) Alternate splicing produces a novel cyclin D1 transcript. Oncogene, 11, 1005-1011.
44. Knudsen, K.E. et al. (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene, 25, 1620-1628.
45. Olshavsky, N.A. et al. (2010) Identification of ASF/SF2 as a critical, allelespecific effector of the cyclin D1b oncogene. Cancer Res., 70, 3975-3984.
46. Paronetto, M.P. et al. (2010) Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res., 70, 229-239.
47. Solomon, D.A. et al. (2003) Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J. Biol. Chem., 278, 30339-30347.
48. Hinds, M.G. et al. (1999) Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat. Struct. Biol., 6, 648-651.
49. Sun, C. et al. (1999) NMR structure and mutagenesis of the inhibitor-ofapoptosis protein XIAP. Nature, 401, 818-822.
50. Miura, K. et al. (2009) cIAP2 as a therapeutic target in colorectal cancer and other malignancies. Expert Opin. Ther. Targets, 13, 1333-1345.
51. Nakamura, N. et al. (2012) ILF3/NF110 is a target of YM155, a suppressant of survivin. Mol. Cell. Proteomics, 11, M111.013243.
52. Carrasco, R.A. et al. (2011) Antisense inhibition of survivin expression as a cancer therapeutic. Mol. Cancer Ther., 10, 221-232.
53. Chang, W.H. et al. (2011) Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib. Cancer Res., 71, 383-392.
54. Sampath, J. et al. (2007) Alternative splice variants of survivin as potential targets in cancer. Curr. Drug Discov. Technol., 4, 174-191.
55. Sawai, K. et al. (2010) Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol. Res., 18, 541-547.
56. Huang, Y. et al. (2011) Expression and prognostic significance of survivin splice variants in diffusely infiltrating astrocytoma. J. Clin. Pathol., 64, 953-959.
57. Vivas-Mejia, P.E. et al. (2011) Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin. Cancer Res., 17, 3716-3726.
58. Pavlidou, A. et al. (2011) Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J. Gastroenterol., 17, 1614-1621.
59. Antonacopoulou, A.G. et al. (2011) The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell. Oncol. (Dordr)., 34, 381-391.
60. Heidelberger, C. et al. (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature, 179, 663-666.
61. Heggie, G.D. et al. (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47, 2203-2206.
62. Miura, K. et al. (2012) S-1 as a core anticancer fluoropyrimidine agent. Expert Opin. Drug Deliv., 9, 273-286.
63. van Kuilenburg, A.B. et al. (2010) Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet., 128, 529-538.
64. Abubaker, J. et al. (2009) Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J. Pathol., 219, 435-445.
65. Novikov, L. et al. (2011) QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol. Cell Biol., 31, 4244-4255.
66. Sporn, J.C. et al. (2012) Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am. J. Pathol., 180, 2516-2526.
67. Abdel-Samad, R. et al. (2011) MiniSOX9, a dominant-negative variant in colon cancer cells. Oncogene, 30, 2493-2503.
68. Sveen, A. et al. (2012) The exon-level biomarker SLC39A14 has organconfined cancer-specificity in colorectal cancer. Int. J. Cancer, 131, 1479-1485.
69. Thorsen, K. et al. (2011) Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol. Cell Proteomics, 10, M110.002998.
70. Graham, L.D. et al. (2011) Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. Genes Cancer, 2, 829-840.
71. Sporn, J.C. et al. (2011) BARD1 expression predicts outcome in colon cancer. Clin. Cancer Res., 17, 5451-5462.
72. Lee, N.P. et al. (2010) Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim. Biophys. Acta, 1806, 138-145.
73. Horváth, H.C. et al. (2010) CYP24A1 splice variants-implications for the antitumorigenic actions of 1, 25-(OH)2D3 in colorectal cancer. J. Steroid Biochem. Mol. Biol., 121, 76-79.
74. Koh, W.P. et al. (2006) Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis, 27, 1797-1802.
75. Plowman, S.J. et al. (2006) The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. Exp. Cell Res., 312, 16-26.
76. Patek, C.E. et al. (2008) The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine. BMC Gastroenterol., 8, 24.
77. Yi, Q. et al. (2011) Alternative spliced variants as biomarkers of colorectal cancer. Curr. Drug Metab., 12, 966-974.
78. Thorsen, K. et al. (2011) Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics, 12, 505.
79. Hayes, G.M. et al. (2007) Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res., 67, 2072-2080.
80. Kole, R. et al. (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov., 11, 125-140.
81. Deleavey, G.F. et al. (2012) Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol., 19, 937-954.
82. Pillay, V. et al. (2011) Antibodies in oncology. N. Biotechnol., 28, 518-529.
83. Tabrizi, M.A. et al. (2009) Translational strategies for development of monoclonal antibodies from discovery to the clinic. Drug Discov. Today, 14, 298-305.
84. Barash, Y. et al. (2010) Deciphering the splicing code. Nature, 465, 53-59.
85. Irimia, M. et al. (2012) Alternative splicing: decoding an expansive regulatory layer. Curr. Opin. Cell Biol., 24, 323-332.
86. Montes, M. et al. (2012) Functional coupling of transcription and splicing. Gene, 501, 104-117.
87. Luco, R.F. et al. (2011) More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Curr. Opin. Genet. Dev., 21, 366-372.
88. de Almeida, S.F. et al. (2012) Design principles of interconnections between chromatin and pre-mRNA splicing. Trends Biochem. Sci., 37, 248-253.
89. Luco, R.F. et al. (2010) Regulation of alternative splicing by histone modifications. Science, 327, 996-1000.
90. McManus, C.J. et al. (2011) RNA structure and the mechanisms of alternative splicing. Curr. Opin. Genet. Dev., 21, 373-379.
91. Will, C.L. et al. (2011) Spliceosome structure and function. Cold Spring Harb. Perspect. Biol., 3, pii: a003707.
92. Gromak, N. (2012) Intronic microRNAs: a crossroad in gene regulation. Biochem. Soc. Trans., 40, 759-761.
93. Esteller, M. (2011) Non-coding RNAs in human disease. Nat. Rev. Genet., 12, 861-874.
94. Turro, E. et al. (2010) MMBGX: a method for estimating expression at the isoform level and detecting differential splicing using whole-transcript Affymetrix arrays. Nucleic Acids Res., 38, e4.